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ABSTRACT
Objectives: We investigated whether lowering of fasting homocysteine concentrations, either
with folic acid or with betaine supplementation, differentially affects vascular function, a
surrogate marker for risk of cardiovascular disease, in healthy volunteers. As yet, it remains
uncertain whether a high concentration of homocysteine itself or whether a low folate status—
its main determinant—is involved in the pathogenesis of cardiovascular disease. To shed light
on this issue, we performed this study.
Design: This was a randomized, placebo-controlled, double-blind, crossover study.
Setting: The study was performed at Wageningen University in Wageningen, the Netherlands.
Participants: Participants were 39 apparently healthy men and women, aged 50–70 y.
Interventions: Participants ingested 0.8 mg/d of folic acid, 6 g/d of betaine, and placebo for 6
wk each, with 6-wk washout in between.
Outcome Measures: At the end of each supplementation period, plasma homocysteine
concentrations and flow-mediated dilation (FMD) of the brachial artery were measured in
duplicate.
Results: Folic acid supplementation lowered fasting homocysteine by 20% ( 2.0 lmol/l, 95%
confidence interval [CI]:  2.3;  1.6), and betaine supplementation lowered fasting plasma
homocysteine by 12% ( 1.2 lmol/l;  1.6;  0.8) relative to placebo. Mean (6 SD) FMD after
placebo supplementation was 2.8 (6 1.8) FMD%. Supplementation with betaine or folic acid
did not affect FMD relative to placebo; differences relative to placebo were 0.4 FMD% (95%CI,
 1.2; 0.4) and  0.1 FMD% ( 0.9; 0.7), respectively.
Conclusions: Folic acid and betaine supplementation both did not improve vascular function
in healthy volunteers, despite evident homocysteine lowering. This is in agreement with other
studies in healthy participants, the majority of which also fail to find improved vascular function
upon folic acid treatment. However, homocysteine or folate might of course affect
cardiovascular disease risk through other mechanisms.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
High plasma total homocysteine concentrations may lead to
cardiovascular disease [1,2], but proof that homocysteine
lowering will prevent these diseases is currently lacking [3].
Some clinical trials of homocysteine lowering through B-
vitamin treatment support this hypothesis [4,5], but others do
not [6–10]. Several years from now, there will be data from
about 50,000 patients that have been supplemented with B-
vitamins or placebo [11]. However, all supplements in these
trials include folic acid, which will make it impossible to
distinguish between the effects of folic acid itself and the
effectsofhomocysteineloweringperse.Inanattempttodoso,
wecomparedtheeffectofhomocysteineloweringviafolicacid
supplementation andviabetainesupplementation onvascular
function. Betaine is involved in the remethylation of homo-
cysteineintomethionineviaadifferentpathwaythanfolicacid
[12], and supplementation with betaine lowers plasma homo-
cysteine in healthy volunteers to a similar extent as folic acid
[13,14]. We assessed vascular function noninvasively through
ﬂow-mediated dilation (FMD) in the brachial artery [15,16].
FMD is considered a good alternative outcome measure for
cardiovascular disease risk. FMD is associated with endothelial
functionincoronaryarteriesofpatients[17,18].Bothcoronary
endothelial function [19,20] and FMD [21–25] are associated
with increased mortality and morbidity risk in patients, as well
as in low-risk populations. Furthermore, in a trial of anti-
hypertensive treatment, those with improved FMD had a more
favorable prognosis than those without improved FMD,
irrespective of blood pressure lowering [26]. This supports
the idea that FMD is a good surrogate marker to assess the risk
of cardiovascular disease in intervention studies in low-risk
populations.Thestudypresentedhereshowsﬁndingsfroma6-
wk randomized, placebo-controlled, double-blind, crossover
study in healthy men and women (50–70 y), investigating
whether folic acid and betaine supplementation differentially
affect FMD of the brachial artery.
METHODS
Participants
Participants were recruited from the pool of volunteers
registered at Wageningen University in the Netherlands.
Eligible volunteers were healthy as assessed by routine
medical screening and a general health questionnaire; were
between 50 and 70 y old; had a plasma total homocysteine
concentration below 26 lmol/l; had no history of cardiovas-
cular disease; had no hypertension; and had not used vitamin
B supplements more than once a week in the 3 mo before
entering the study. Out of 87 eligible participants, 40
participants (23 males) with the highest plasma total
homocysteine concentrations (range, 10.2–21.7 lmol/l) were
included in this placebo-controlled, double-blind, crossover
study.
The study was conducted at the Division of Human
Nutrition at Wageningen University (Wageningen, the
Netherlands). The local medical ethics committee approved
the protocol, and all volunteers gave their written informed
consent.
Interventions
Participants were randomly assigned to one out of six
treatment orders, and they received each of the following
supplements for 6 wk, with a 6-wk washout in between: (a) 6 g/
d of betaine (BUFA B.V. Pharmaceutical Products, Uitgeest,
the Netherlands); (b) 0.8 mg/d of folic acid mixed with 6 g of
lactose (BUFA B.V.); (c) 6 g/d of lactose (placebo; BUFA B.V).
The study supplements were dissolved in water and ingested
twice per day, one half of the daily dose after breakfast and
the other half after the evening meal. We used a supplemen-
tation dose of 6 g/d of betaine because we anticipated that
this dose would lower fasting plasma homocysteine concen-
trations to a similar extent as 0.8 mg/d of folic acid [13,14,27].
Objectives
We investigated whether lowering of fasting homocysteine
concentrations, either with folic acid or with betaine supple-
mentation, differentially affects vascular function, a surrogate
markerforriskofcardiovasculardisease,inhealthyvolunteers.
www.plosclinicaltrials.org June | 2006 | e10 0002
Homocysteine Lowering Does Not Affect FMD
Editorial Commentary
Background: Evidence from observational studies indicates a link
betweenhighconcentrationsofhomocysteine(anaminoacid)intheblood
andincreasedrisk ofcardiovasculardisease.However,thebasisforthelink
between homocysteine concentrations and cardiovascular disease risk is
not clear. Supplementing the diet with B-vitamins lowers homocysteine
levels, and large-scale trials are underway that will determine whether B-
vitamin supplementation has an effect on cardiovascular outcomes, such
asheartattacksandstrokes.Thesetrialsalsoinvolveadministrationoffolic
acid as well as other B-vitamins. It is not obvious, however, whether the
effects of B-vitamin supplementation arise as a result of homocysteine
lowering or via some other biochemical pathway.
What this trial shows: Olthof and colleagues aimed to further
understand the effects of homocysteine lowering by randomizing 40
healthy volunteer participants to receive either folic acid supplementa-
tion; placebo; or betaine, a nutrient that lowers homocysteine levels via a
different biochemical pathway than folic acid. Each participant in the trial
received each supplement for 6 wk, with a 6-wk washout period before
the next supplement was given. The researchers then used a technique
called flow-mediated dilation (FMD) to measure functioning of the main
artery of the upper arm, as a surrogate for cardiovascular disease risk. In
this trial, both folic acid and betaine supplementation significantly
lowered homocysteine levels over the 6-wk supplementation period.
However, both forms of supplementation failed to result in any
significant change in functioning of the artery, as measured using FMD.
Strengths and limitations: In this trial 40 participants were recruited,
and 39 were followed up to trial completion. A crossover design was
used, with each participant receiving each supplement and a placebo in
sequence. This method enabled a smaller number of participants to be
used to answer the question of interest, as compared to parallel-group
designs. The majority of participants in the trial were followed up.
However, the trial’s outcomes are surrogates for cardiovascular disease
risk, measured over fairly short time periods, and no clinical outcomes
were examined.
Contribution to the evidence: This trial adds to the evidence on the
effects of nutrient supplementation on surrogate outcomes for
cardiovascular disease risk. The results show that over a 6-wk study
period, these surrogate outcomes are not affected by either folic acid or
betaine supplementation.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.Outcomes
FMD and plasma homocysteine concentrations were primary
outcome measures. Concentrations of vitamins B6,B 12, and
folate in blood were secondary outcome measures.
FMD. Brachial artery measurements were done in partic-
ipants following an overnight fast at the end of each
treatment period on days 41 and 43. We measured each
participant on two separate days after each 6-wk treatment
period to reduce the variation within participants. The
within-participant coefﬁcient of variation (CV ¼f SD/meang
3 100%) was 65% in our study, and this corresponded to
previous measurements in our laboratory [28,29].
On each measurement day, participants rested on a bed for
15 min in a temperature-controlled room (20 8C  25 8C) and
then we measured endothelium-dependent FMD of the
brachial artery using a 7.5 MHz linear-array transducer of
an ATL Ultramark 9 HDI duplex scanner (Philips Medical
Systems, Bothell, Washington, United States). The measure-
ments were done at the brachial artery of the right arm, at the
site of the antecubital crease, with an inﬂatable cuff around
the forearm. Arm and ultrasound transducer were held in
position with a specially designed ﬁxture (TAF, developed by
Meijer, Vascular Imaging Center, Julius Center for Health
Sciences and Primary Care, University Medical Centre
Utrecht, Utrecht, the Netherlands) [29]. We chose a segment
of the artery of at least 10 mm in length with clear lumen and
distinctive vessel walls. All images were 103 zoomed and
electronically focused. We ﬁrst obtained an optimal two-
dimensional B-mode ultrasound image of the brachial artery
at rest and recorded three baseline images to measure
baseline diameter. We then either inﬂated the cuff around
the lower arm to a pressure of 200 mmHg or we inﬂated the
cuff 50 mmHg above systolic blood pressure in cases in which
the systolic blood pressure was .150 mmHg. The pressure
was kept constant for 5 min to induce ischemia in the
forearm and hand, and then the cuff was deﬂated and image
recording was started. In the next 5 min, images of the
brachial artery were frozen every 15 s. All measurements were
done at the end-diastole by the use of the R-wave of the
electrocardiogram. All images were recorded on super-VHS
videotape for ofﬂine analysis.
The ofﬂine reading of ultrasound examinations was done
using Brachial Tools, Version 3.2.6 (Medical Imaging Appli-
cations, Coralville, Iowa, United States), as has been described
in detail elsewhere [29]. One reader, who was unaware of
treatment allocation, read all images at the Vascular Imaging
Centre of the University Medical Center Utrecht (Utrecht, the
Netherlands). Each scan was read in duplicate, to limit reading
variation. The coefﬁcient of variation (CV ¼f SD/meang 3
100%) in calculated FMD% between readings was 22%. The
reader traced the trailing edge of the adventitia–media
interface at the near wall and the leading edge of the media–
adventitia interface at the far wall of the brachial artery over a
length of at least 3 mm. The distance between these interfaces
reﬂects the lumen diameter. FMD was computed as the
percent increase in arterial diameter: FMD% ¼f (maximum
minus baseline)/baselineg 3 100%. For reasons of clarity, we
use ‘‘FMD%’’ as a unit of FMD measurements.
Blood sampling and laboratory analyses. Venous blood was
taken from the antecubital vein following an overnight fast
on days 41 and 43 of each treatment period. Blood for
analysis of total homocysteine was collected in vacutainer
tubes containing EDTA. Samples were mixed and put on ice
immediately after collection. Within 30 min, samples were
centrifuged for 20 min at 2000 3 g at 4 8C. For analyses of
vitamins B12 and folate, blood was collected in vacutainer
tubes containing clot activator and a gel to separate serum
and cells. About 30 min after collection, samples were
centrifuged for 15 min at 2000 3 g at 4 8C. For analysis of
vitamin B6, blood was collected in lithium–heparin vacu-
tainer tubes. All samples were stored below  70 8C. Samples
were coded to hide the identity and treatment of partic-
ipants. All samples obtained from one participant were
analyzed in the same run.
Total homocysteine concentrations (the sum of all oxidized
and reduced forms of homocysteine) were measured by high
performance liquid chromatography with ﬂuorescence detec-
tion [30]. Serum folate and vitamin B12 were measured using a
commercial chemiluminescent immunoassay system (IMMU-
LITE 2000, Diagnostic Products Corporation, Los Angeles,
California, United States) [31]. The determination of vitamin
B6 as pyridoxal-59-phosphate in whole blood was performed
with an high performance liquid chromatography technique
[32], using precolumn derivatization with semicarbazide to
obtain pyridoxal-59-phosphate–semicarbazone [33].
Standardization procedures. During the study, participants
were not allowed to consume supplements containing B-
vitamins, antioxidant vitamins (A, beta-carotene, C, and E), or
n-3 fatty acids/ﬁsh oil supplements, and participants were
instructed to maintain their physical activity level, dietary
habits, and smoking habits during the study.
Participants ate their self-selected diets, except on the days
before blood was sampled and FMD measurements were
performed (i.e., days 40 and 42 of each supplement period).
On these days, we provided the participants with a stand-
ardized breakfast, lunch, dinner, and snacks. The foods
consisted of normal food products, but foods rich in protein,
folic acid, betaine, or choline were avoided. Participants were
not allowed to consume any of their own foods during these
days, except for coffee and tea. On the ﬁrst day that
participants received the standardized foods, they could
choose the amounts they wanted to eat of the foods we
provided and of coffee and tea. On all following standardized
days, participants received the standardized foods in amounts
similar to what they had consumed on the ﬁrst day and were
instructed to consume the same amounts of coffee and tea as
they did on the ﬁrst day. Participants were instructed to eat
everything that we provided and not to eat anything else on
that day. Participants prepared and ate the foods at home.
Coffee and tea consumption and smoking were not allowed
after 6 P.M., and dinner had to be consumed before 8 P.M.
From 10 P.M. until after the measurements the next
morning (blood sampling and FMD), participants were not
allowed to smoke, eat, or drink, except for water. After the
measurements, a breakfast without restrictions was provided.
Sample Size
We calculated that 30 participants would be required to
detect an absolute difference of 2 FMD% relative to placebo
(power ¼ 0.8, a ¼ 0.05). We included 40 participants in our
study, anticipating that some participants might withdraw.
www.plosclinicaltrials.org June | 2006 | e10 0003
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A person not further involved in the study assigned codes to
the study treatments, randomly allocated the selected
participants to one out of six treatment orders, and kept
the key in a sealed envelope. The participants and all others
involved in this study were unaware of treatment allocation.
The principal investigator performed unblinding of the
treatment allocation only after the study had ended and
laboratory analyses were complete.
Betaine has a bitter taste, whereas lactose is sweet. To avoid
unblinding of the study by distinct differences in taste
between supplements, 2 mg of quinine (chinine hydro-
chloridum; BUFA B.V. Pharmaceutical Products) was added
per 6 g of each supplement.
Statistical Methods
For each treatment period and for each participant, we ﬁrst
averaged the duplicate readings of FMD measured on day 41
and day 43 and then averaged these mean readings of days 41
and 43. For concentrations of homocysteine and B-vitamins,
we averaged values of days 41 and 43 for each participant in
each treatment period. Data were analyzed by the linear
mixed effects models procedure in SPSS (Version 12.0).
Tukey’s procedure was used for pairwise comparisons and for
the calculation of 95% conﬁdence intervals (CI) between
treatments. Carryover effects were checked by introducing a
treatment-by-period interaction term in the model. All
statistical analyses were performed with SPSS, Version 12.0.
RESULTS
Participant Flow and Recruitment
Participant ﬂow is shown in Figure 1. Volunteers were
recruited from June to September 2002. The intervention
started October 2002 and was completed in June 2003.
Baseline Data
Participant characteristics at screening are shown in Table 1.
Numbers Analyzed
Of the 40 initial participants, 39 completed the study. One
male participant withdrew from the study because he moved
to another country.
Outcomes and Estimation
Folic acid supplementation lowered fasting concentrations of
homocysteine by 20% ( 2.0 lmol/l, 95%CI: 2.3; 1.6) relative
to placebo (Table 2). Betaine supplementation lowered
fasting concentrations of homocysteine by 12% ( 1.2 lmol/
l,  1.6;  0.8) relative to placebo.
FMD was not affected by supplementation with folic acid
or betaine relative to placebo (Table 2; Figure 2). Relative to
placebo treatment, the mean difference in FMD was only 0.1
FMD% (95%CI,  0.9; 0.7) after folic acid treatment and  0.4
FMD% ( 1.2; 0.4) after betaine treatment. In addition, the
mean (6 SD) fasting baseline diameter of the brachial artery
following placebo, folic acid, and betaine supplementation
was 4.33 6 0.62 mm, 4.31 6 0.60 mm, and 4.44 6 0.64 mm,
respectively. Neither the baseline diameter nor the maximum
diameter was affected by folic acid or betaine treatment
relative to placebo.
As expected, concentrations of serum folate were increased
more than 2-fold after folic acid treatment relative to
concentrations after placebo treatment (þ37 nmol/l, 32; 42)
and after betaine treatment (þ39 nmol/l, 34; 44) (Table 2). This
also indicates good compliance to intake of the supplements.
Concentrations of vitamins B12 and B6 did not change during
folic acid supplementation relative to placebo. Betaine
supplementation did not affect serum folate concentrations
or concentrations of vitamins B12 and B6 relative to placebo.
However, serum concentration of vitamin B12 was slightly
higher (þ24 pmol/l, 4; 44) after betaine supplementation than
after folic acid supplementation. The treatment-by-period
interactions test indicated that there were no important
carryover effects present (data not shown).
Adverse Events
No serious adverse events were reported in this study.
Nonserious adverse events occurred 112 times in 31
participants. The adverse events were diverse and unlikely
related to the treatment. Most commonly occurring events
were headache/migraine (59 times) and common cold/
inﬂuenza (29 times).
DISCUSSION
Interpretation
In our study, homocysteine lowering via folic acid and via
betaine supplementation both failed to affect FMD in healthy
elderly volunteers. This suggests that homocysteine, if
involved in pathogenesis of cardiovascular disease, does not
Figure 1. CONSORT Flowchart Participant Flow and Recruitment
DOI: 10.1371/journal.pctr.0010010.g001
.......................................................................................
Table 1. Participant Characteristics at Screening (n ¼ 40)
Characteristic Mean 6 SD
Age (y) 59 6 5
BMI (kg/m
2) 25.2 6 2.8
Systolic blood pressure (mmHg) 130 6 16
Diastolic blood pressure (mmHg) 74 6 10
Total homocysteine (lmol/l) 12.0 6 2.0
Folate (nmol/l) 16.8 6 7.9
Vitamin B12 (pmol/l) 347 6 111
Vitamin B6 (nmol/l) 77.1 6 23.7
Total cholesterol (mmol/l) 5.8 6 0.6
DOI: 10.1371/journal.pctr.0010010.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Homocysteine Lowering Does Not Affect FMDexert its action through a mechanism related to vascular
function in healthy individuals. This is the ﬁrst study to our
knowledge that has compared the effects of two different
homocysteine-lowering components on FMD in order to
distinguish between effects of homocysteine itself and effects
of folic acid.
We are conﬁdent that we designed and performed our
study well. We selected apparently healthy elderly people with
slightly elevated plasma homocysteine concentrations, who
are expected to have a greater response to the homocysteine-
lowering interventions than randomly selected individuals.
The FMD measurement itself was performed similar to
previous studies done in our laboratory. In one study,
replacement of dietary saturated fatty acids by dietary trans
fatty acids impaired FMD after 4 wk of intervention [34], but
no effect was found of a low-fat diet versus a high-oil diet on
FMD [35].
We standardized the FMD measurement to a maximum of
what is possible in a free-living situation. To reduce the
variation in the FMD measurement due to diet, we provided
all foods the day preceding the FMD measurements, and we
standardized coffee and tea consumption. Further, we stand-
ardized the timing of the last time eating and smoking on the
evening before measurements. During the entire study, we
also asked the volunteers to keep physical activity, smoking,
and dietary patterns as usual. To limit the inﬂuence of
variation in FMD between participants, we chose a crossover
design in our study, so that each participant was his or her
own control. In addition, we know that the within-participant
variability of the FMD measurement is large [28]. Therefore,
we did duplicate FMD measurements in each participant on
each intervention, and we also did the reading of the
videotapes for each of the FMD measurement in duplicate.
Indeed, the narrow 95%CI we found for the difference in
FMD indicate that the power for our study was more than
sufﬁcient. Our study was powered to detect an absolute
difference of 2 FMD% between the treatments and placebo,
as this effect is considered to be clinically relevant and is also
used in power calculations in other studies [36–38]. If we
assume that the 95%CIs in our study contain the true effect,
then we can say that the beneﬁcial effect on FMD could be
maximally þ0.7 FMD% for folic acid and þ0.4 FMD% for
betaine in our population. It is unlikely that we missed a
biologically relevant effect through chance ﬂuctuations.
Overall Evidence and Generalizability
We are not aware of other published studies that have
investigated effects of betaine supplementation on FMD.
Betaine lowered plasma homocysteine as expected [13,14],
but we previously reported that betaine supplementation—
unlike folic acid supplementation—increased LDL cholester-
ol concentrations by ;11% and increased triacylglycerol
concentrations by ;13% [39]. Consequently, we cannot
completely exclude the possibility that these increases in
blood lipids induced by betaine supplementation negatively
affected FMD [40] and thereby counteracted the potential
positive effect of homocysteine lowering. However, this seems
unlikely, since folic acid supplementation also lowered
homocysteine and did not affect FMD either.
The absence of an effect of folic acid on FMD in our study
is in line with results from other studies in healthy volunteers
that show that chronic folic acid supplementation does not
affect FMD in healthy volunteers. Only two out of eight
studies in healthy volunteers reported an improvement in
FMD upon long-term folic acid supplementation; the other
studies did not ﬁnd an effect of supplementation with folic
acid alone, or in combination with other B-vitamins, on FMD
(Table 3). However, it should be noted that one of the two
studies [41] that found an improvement of FMD upon folic
acid supplementation reported that participants ingested
folic acid just before measurement of FMD. Therefore, the
improvement in FMD they found could be caused by an acute
effect of folic acid on FMD and not by homocysteine-lowering
per se [42–44]. However, in our other study conducted at the
same time as this one, we found no effect of a single dose of
folic acid on FMD following a methionine load [45]. A second
study [46] does not report when participants ingested the last
dose of folic acid. In our study reported here, vascular
function was measured in participants after they had fasted
overnight, to ensure we measured chronic rather that acute
effects of the supplements. The results of the study reported
.......................................................................................
Table 2. FMD%, Concentrations of Total Plasma Homocys-
teine, and Concentrations of B-Vitamins in 39 Participants
Who Ingested Placebo, 0.8 mg/d of Folic Acid, and 6 g/d of
Betaine in Random Order for 6 Wk Each, in Crossover Design
Outcome Measure Mean 6 SD
Placebo Folic Acid Betaine
FMD% 2.8 6 1.8 2.8 6 1.9 2.4 6 1.7
Plasma homocysteine (lmol/l) 9.9 6 1.6 8.0 6 1.3
a 8.7 6 1.4
b
Serum folate (nmol/l) 16.1 6 4.9 53.0 6 17.7
a 14.4 6 3.4
c
Serum vitamin B12 (pmol/l) 286 6 121 277 6 105
d 301 6 121
d
Blood vitamin B6 (nmol/l) 63.4 6 14.3 62.9 6 13.9 63.8 6 11.1
ap , 0.001 versus placebo and betaine treatments.
bp , 0.001 versus placebo and folic acid treatments.
cp , 0.001 versus folic acid treatment.
dp , 0.02 between folic acid and betaine treatment.
DOI: 10.1371/journal.pctr.0010010.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. Individual Values of FMD (FMD%) of 39 Participants Who
Ingested Placebo, 0.8 mg/d of Folic Acid, and 6 g/d of Betaine in Random
Order for 6 Wk Each
Each spot represents the mean of duplicate FMD measurements at the end of
the treatment period in one participant; the line represents the mean FMD for
each treatment.
DOI: 10.1371/journal.pctr.0010010.g002
www.plosclinicaltrials.org June | 2006 | e10 0005
Homocysteine Lowering Does Not Affect FMD.......................................................................................................................................................................................
Table 3. Overview of Placebo-Controlled Studies into the Effects of Folic Acid Supplementation on Vascular Function,
Measured through FMD
Reference Participants Participant Characteristics Study Design Findings
Bellamy et al. [46] Healthy
volunteers
18 participants, with
plasma homocysteine .13 lmol/l
at entry (age not reported)
& Randomized, double-blind,
placebo-controlled crossover study
& Oral folic acid (5 mg/d) and placebo
for 6 wk each (6-wk washout)
& Plasma homocysteine levels were 28% lower
after folic acid (8.7 6 2.5 lmol/l)
than after placebo supplementation
(12.1 6 3.6 lmol/l; p ¼ 0.003)
& Folic acid improved FMD relative to placebo
(2.5% 6 0.4% relative to
1.1% 6 0.3 %; p ¼ 0.02)
Woo et al. [41] Healthy
volunteers
17 participants
(mean 6 SD age:
54 6 10 y; 15 males)
& Randomized, double-blind,
placebo-controlled, crossover trial
& Oral folic acid (10 mg/d) and placebo
for 8 wk (4-wk washout)
& Plasma homocysteine levels were lower
after folic acid (8.1 6 3.1 lmol/l)
than after placebo supplementation
(9.5 6 2.5 lmol/l; p ¼ 0.03)
& Folic acid supplementation improved
FMD relative to placebo
(8.2% 6 1.6% vs. 6% 6 1.3%; p , 0.001)
Wilmink et al. [58] Healthy
volunteers
20 participants
(mean age: 23 6 3.4 y; 10 males)
& Randomized, double-blind,
placebo-controlled, crossover study
& Oral folic acid (10 mg/d)
and placebo for 2 wk (8-wk washout)
& Fasting homocysteine was 2.2 lmol/l lower
after the folic acid period
(5.0 6 0.7, mean 6 SD) than after placebo
(7.2 6 2.1 lmol/l) (p , 0.05)
& Folic acid treatment did not affect FMD
van Dijk et al. [59] Healthy
volunteers
130 participants
(age 45; siblings of patients
with atherothrombotic disease)
& Randomized, double-blind,
placebo-controlled, parallel study
& Treatment for 1–2 y:
(1) 5 mg/d folic acid þ 250 mg/d
pyridoxine (n ¼ 63; age: 45 6 7y ;
37 males)
(2) Placebo (n ¼ 67; age: 46 6 8y ;
29 males)
& Fasting homocysteine decreased by 40%
in B-vitamin group relative to the
placebo group (p , 0.001)
& No effect of B-vitamin treatment on FMD
Pullin et al. [60] Healthy
volunteers
126 participants
(42 of each MTHFR genotype
age: 39 6 12 y, 53 males)
& Randomized, placebo-controlled,
crossover study
& Treatments, each for 4 mo:
(1) Placebo (dietary folate intake,
;200 lg/d)
(2) 400 lg/d of dietary folate
(total folate intake, ;600 lg/d)
(3) 400 lg of folic acid
(total folate intake, ;600 lg/d)
& Plasma homocysteine decreased by 14%
and 16% after dietary folate and after
folic acid supplementation, respectively
& No effect of treatment on FMD
irrespective of the MTHFR genotype
Hirsch et al. [61] Healthy
volunteers
20 participants
and 20 age-matched patients
with hyperhomocysteinemia
(age: 30 6 6y )
& Randomized, double-blind,
placebo-controlled parallel study
& 8-wk intervention with 0.6 mg/d of
folic acid þ 0.8 mg of
vitamin B12 þ 2 mg of vitamin B6
(nine pairs, n ¼ 18), or placebo
(11 pairs, n ¼ 22)
& Plasma homocysteine decreased significantly
due to vitamin treatment in normohomocys-
teinemic as well as in hyperhomocysteinemic
participants (p , 0.0001)
& Vitamin treatment did not affect FMD
Woodman
et al. [36]
Healthy
volunteers
26 participants (age: 49 6 2y )
with high homocysteine
at baseline (15.6 6 1.5 lmol/l)
& Randomized, double-blind,
placebo-controlled, crossover study
& Folic acid decreased homocysteine by 34%
& Folic acid treatment did not affect FMD
& 8-wk intervention with 5 mg/d of
folic acid or placebo (4-wk washout)
Carlsson
et al. [37]
Healthy
volunteers
20 participants (age: 78 6 1y ;
mean homocysteine concentration:
12.8 6 0.5 [SEM] lmol/l)
& Single-blind intervention study
& All participants were treated
sequentially with four treatments
for 10 wk each:
(1) Placebo
(2) Multivitamins: 400 lg of folic acid
þ 6 mg of vitamin B6 þ 25 lgo f
vitamin B12 daily
(3) Placebo
(4) Multivitamins: 400 lg of folic acid
þ 6 mg of vitamin B6 þ 25 lgo f
vitamin B12, and 1 mg of folic acid daily
& Multivitamin intake decreased homocysteine
concentrations by 6% (p ¼ 0.06), and
multivitamin þ 1 mg folic acid intake did
not further lower homocysteine; during the
40-wk study, plasma homocysteine was
decrease by 11% (p-trend ¼ 0.03)
& FMD did not improve after multivitamins
only or after multivitamins þ 1 mg folic acid
relative to the preceding placebo period
Thambyrajah
et al. [52]
Patients 100 patients with
chronic renal failure
(mean age: 62 y; range: 22–84 y)
& Randomized, double-blind,
placebo-controlled parallel trial
& 12-wk intervention with:
(1) Placebo (n ¼ 50)
(2) 5 mg/d of folic acid (n ¼ 50)
& Homocysteine concentrations were
25% lower in the folic acid group relative
to the placebo group
& Folic acid supplementation did not affect FMD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3. Continued
Reference Participants Participant Characteristics Study Design Findings
Title et al. [49] Patients 75 patients
with CAD (age: 59 6 10 y)
& Randomized, double-blind,
placebo-controlled parallel trial
& Folic acid reduced plasma homocysteine by
11% (p ¼ 0.23) relative to placebo
& 4-mo intervention with: & Folic acid improved FMD from 3.2% 6 3.6%
at baseline to 5.2% 6 3.9% after intervention
(p ¼ 0.04 folic acid versus placebo)
& The improvement in FMD correlated with the
reduction in homocysteine (r ¼ 0.5, p ¼ 0.01)
& Folic acid þ antioxidants reduced
plasma homocysteine by 9% (p ¼ 0.56)
relative to placebo
& Folic acid þ antioxidants did not improve FMD
(2.6% 6 2.4% at baseline; 4.0% 6 3.7%
after intervention, p ¼ 0.45, folic acid þ
antioxidants versus placebo), relative to placebo
(1) Placebo (n ¼ 25)
(2) 5 mg/d of folic acid
(n ¼ 25)
(3) 5 mg/d of folic acid þ
antioxidant vitamins C
(2 g/d) and E (800 IU/d)
(n ¼ 25)
Chambers
et al. [50]
Patients 89 male patients
with coronary heart disease
(mean age: 56 y; range: 39–67 y)
& Randomized, double-blind,
placebo-controlled, parallel study
& B-vitamins reduced plasma homocysteine by
;30% (p , 0.001) relative to the placebo group
& Treatments for 8 wk: & FMD is improved in B-vitamin group
(þ1.5% 6 3.5% change from baseline) relative
to placebo ( 0.3% 6 2.5%) (p ¼ 0.008)
& There is an independent relationship between
FMD and free, but not protein-bound,
homocysteine concentrations
(1) 5 mg/d of folic acid
þ 1 mg/d of vitamin B12
(n ¼ 59)
(2) Placebo (n ¼ 30)
Thambyrajah
et al. [38]
Patients 86 patients with CAD and
plasma homocysteine .11 lmol/l
(age: 63 y; range: 46 – 79 y; 79 males)
& Randomized, double-blind,
placebo-controlled, parallel study
& Folic acid reduced plasma homocysteine
by 24% (p , 0.001) relative to placebo
& 12-wk intervention with: & No significant difference in FMD between
folic acid and placebo group, but the
improvement in FMD was larger in the
folic acid group (þ1.2%; 95%CI, 0.7%–1.8%)
than in the placebo group
(þ0.4%;  0.3% to 1.1%) (p ¼ 0.07)
(1) 5 mg/d of folic acid (n ¼ 43)
(2) Placebo (n ¼ 43)
Doshi et al. [44] Patients 52 patients with CAD
(age: 57 6 8y )
& Randomized, double-blind,
placebo-controlled,
crossover trial
& 6-wk intervention with 5 mg/d
of folic acid and placebo
(4-mo washout)
& Folic acid decreased plasma homocysteine
concentrations by ;14% (10.8 lmol/l after
placebo period; 9.3 lmol/l after folic acid period)
& Folic acid supplementation improved FMD
significantly relative to placebo (p , 0.001)
& Decreases in plasma homocysteine were not
correlated with improvement in FMD
Bennet-Richards
et al. [53]
Patients 25 normotensive children
(age: 12 6 3y )
with chronic renal failure
& Randomized, double-blind,
placebo-controlled,
crossover trial
& 8-wk intervention with 5 mg/m
2
folic acid and placebo (8-wk
washout)
& Total homocysteine concentrations decreased
significantly during folic acid supplementation
(from 10.3 6 4.2 to 8.6 6 2.3 lmol/l; p ¼ 0.03),
but not during placebo (from 9.0 6 2.2 to
9.8 6 2.7 lmol/l; p ¼ 0.3)
& Final FMD after the folic acid period and after
placebo period were not significantly different
Doshi et al. [43] Patients 33 patients with CAD
(age: 55 6 7y )
& Randomized, double-blind,
placebo-controlled, parallel study
& 6-wk intervention:
(1) 5 mg/d of folic acid (n ¼ 16)
(2) Placebo (n ¼ 17)
& FMD measured before and
2 and 4 h after first dose of
folic acid, and after 6 wk of
treatment
& Plasma homocysteine was significantly lower
(;20%) in the folic acid group relative to the
placebo group after 6-wk intervention (p , 0.001)
& No difference in plasma homocysteine between
the intervention groups during initial 4 h after
intake of supplements on the first day
& FMD improved within 2–4 h after first dose of folic
acid, which persisted after 6 wk of folic acid intake
& No correlation between FMD improvement and
reduction in plasma homocysteine or changes
in serum folate
Sydow et al. [54] Patients 27 patients with peripheral
arterial occlusive disease
& Randomized, placebo-controlled,
parallel study
& 8-wk intervention with:
(1) 10 mg/d of folic acid
þ 20 mg/d of vitamin B6
þ 0.2 mg/d of vitamin B12
(n ¼ 9; 69 6 4y )
(2) 24 g/d of arginine
(n ¼ 9; 64 6 4y )
(3) Placebo (n ¼ 9; 69 6 3y )
& Mean plasma homocysteine concentrations at
baseline were 15.0 lmol/l; after 8-wk treatment
with B-vitamins, plasma homocysteine was
decreased to 8.7 lmol/l; neither arginine nor
placebo treatment affected plasma
homocysteine concentrations
& Neither B-vitamin treatment nor placebo affected
FMD; arginine treatment enhanced FMD from 7.2
FMD% at baseline to 10.2 FMD% after 8 wk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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effects of acute homocysteine lowering on FMD following
methionine loading [45]. Also, our ﬁndings are in line with
results from recent placebo-controlled trials that found no
effect of B-vitamin supplementation on secondary preven-
tion of cardiovascular disease [6,7,9,10].
Of course, it remains possible that homocysteine lowering
affects vascular function only in patients with cardiovascular
disease or participants who have other risk factors for
cardiovascular disease [47]. However, data on effects of folic
acid on FMD in high-risk populations are inconsistent (Table
3). Six out of 11 studies stated that FMD improved upon folic
acid supplementation [43,44,48–51]. The study from Madha-
van et al. [48] found an improvement in FMD only upon
supplementation of high doses of folic acid (5 mg/d), but not
on supplementation of low doses of folic acid (0.4 mg/d) in
coronary artery disease (CAD) patients. Two studies in
patients with renal failure [52,53], one study in patients with
CAD [38], one study in patients with peripheral arterial
disease [54], and one study in hypercholesterolemic patients
receiving statins [55] found no effect of folic acid on FMD
relative to placebo. Therefore, similar to the ﬁnding in
healthy volunteers, studies in patients do not convincingly
show that folic acid supplementation improves FMD.
Study Limitations
Although we have performed the FMD measurement with
utmost care, there are some methodological issues to discuss.
First, we did not perform a nitric oxide-independent vaso-
dilation test, usually done with sublingual nitroglycerine
(NTG). The rationale for such a test is to show whether or not
the artery is capable of responding to nitric oxide directly
given to participants (endothelium-independent vasodila-
tion). Since we selected healthy participants in our study,
we assumed that all participants would have an FMD
response, and we therefore did not conﬁrm this with an
NTG test. Moreover, treatment effects on the NTG test were
not expected [34,56,57]. As we have seen an FMD response in
all of our participants, we do not think that the lack of NTG
measurements affects the validity of our ﬁndings.
Second, we did not perform Doppler measurements after
the cuff release. The Doppler measurements reﬂect the
stimulus (i.e., the blood ﬂow) that elicits the FMD response,
and through these measurements one may examine whether
the differences between participants and between visits are
due to differences in exposure to increased blood ﬂow. We
did not perform the Doppler measurements in order to
optimize the measurements of the B-mode imaging. The time
window to switch between B-mode and the Doppler mode in
the ultrasound machine was too short to perform valid
Doppler measurements and at the same time capture reliable
images for lumen diameter measurements within the ﬁrst
period after cuff release, which is the most important phase
in which dilation occurs. However, it is highly unlikely that
the stimulus will differ between visits, as the measurements
were done in a standardized manner, by the same technicians
using an identical protocol. Moreover, the FMD was
measured in duplicate on each treatment, which minimized
variations in the FMD responses that were not due to the
treatments. Therefore, the validity of our ﬁndings is not
severely hampered by the lack of the Doppler measurement.
Finally, we added a small amount of quinine to all of the
supplements in order to keep the study blinded by masking
the original tastes of the supplements. Especially betaine has a
somewhat distinct, unpleasant taste. Quinine is a ﬂavoring
agent, approved by the Food and Drug Administration in
beverages up to 83 mg/l. We added 2 mg of quinine to each
daily portion of the supplements, and we are not aware of any
effects of such a small dose on vascular function. In addition,
b e c a u s ew ea d d e dq u i n i n et oa l lo ft h es u p p l e m e n t s ,
including placebo, it is highly unlikely that this would have
inﬂuenced the results of this study.
.......................................................................................................................................................................................
.
Table 3. Continued
Reference Participants Participant Characteristics Study Design Findings
Madhavan
et al. [48]
Patients 75 patients with CAD & Randomized, placebo-controlled,
parallel study
& High-dose, but not low-dose, folic acid
treatment improved FMD, despite a
significant reduction in plasma
homocysteine concentrations in both folic
acid treatment groups relative to placebo
& 6-wk intervention with:
(1) High-dose folic acid (5 mg/d)
(2) Low-dose folic acid (0.4 mg/d)
(3) Placebo
Lekakis et al. [55] Patients 34 hypercholesterolemic patients
receiving statins
& Randomized, placebo-controlled,
parallel study
& Homocysteine concentrations were not
reported
& 4-wk intervention with: & Within the folic acid treatment group,
the FMD improved after treatment
(4.7% 6 3.2% to 7.1% 6 3.1%; p ¼ 0.02),
whereas there was no improvement after
placebo (5.7% 6 3.8% to 5.6% 6 2.2%, ns)
(1) 5 mg/d of folic acid (n ¼ 17)
(2) Placebo (n ¼ 17)
& Final FMD between the folic acid-treated
group and the placebo group were not
significantly different
Pena et al. [51] Patients 36 patients with type 1 diabetes
(mean 6 SD age: 13.6 6 2.5 y)
& Randomized, double-blind,
placebo-controlled, crossover trial
& 8-wk intervention with 5 mg/d
of folic acid and placebo
(8-wk washout)
& Plasma homocysteine concentrations
did not change significantly, but were
already low at baseline (;5 lmol/l)
& Folic acid supplementation improved FMD
significantly relative to placebo (p , 0.001)
DOI: 10.1371/journal.pctr.0010010.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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CONCLUSION
We showed that neither long-term folic acid nor betaine
supplementation affects vascular function in healthy elderly
volunteers, despite effective homocysteine lowering. This is in
line with ﬁndings from other studies, most of them showing
no effect of chronic folic acid supplementation on vascular
function in healthy volunteers. This may indicate that
homocysteine is not causally related to cardiovascular disease,
but leaves open the possibility that homocysteine affects
cardiovascular disease risk through mechanisms other than
impaired vascular function.
SUPPORTING INFORMATION
CONSORT Checklist
Found at DOI: 10.1371/journal.pctr.0010010.sd001 (53 KB DOC).
Trial Protocol
Found at DOI: 10.1371/journal.pctr.0010010.sd002 (115 KB DOC).
Alternative Language Abstract
Translation of the abstract into Dutch by Margreet R. Olthof.
Found at DOI: 10.1371/journal.pctr.0010010.sd003 (28 KB DOC).
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